Search research articles
Contact Us
Filters
Showing results (11-20 of 18) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 18 results.
Urology
|
March 25, 2017
Prospective Case-crossover Study Investigating the Possible Association Between Nonarteritic Anterior Ischemic Optic Neuropathy and Phosphodiesterase Type 5 Inhibitor Exposure
Evelyn M Flahavan, Hu Li, Komal Gupte-Singh, et al.
Headache
|
November 29, 2020
Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine
Janet H Ford, Tobias Kurth, Amaal J Starling, et al.
Cephalalgia : an International Journal of Headache
|
November 4, 2020
Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine
David W Dodick, Erin G Doty, Sheena K Aurora, et al.
The Journal of Headache and Pain
|
February 26, 2020
Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study
Richard B Lipton, Louise Lombard, Dustin D Ruff, et al.
Cephalalgia : an International Journal of Headache
|
May 21, 2019
Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure
Dustin D Ruff, Janet H Ford, Antje Tockhorn-Heidenreich, et al.
Expert Review of Neurotherapeutics
|
October 22, 2015
Atomoxetine monotherapy compared with combination therapy for the treatment of ADHD: a retrospective chart review study
David B Clemow, Oren W Mason, Elias H Sarkis, et al.
Journal of the American Academy of Child and Adolescent Psychiatry
|
August 23, 2007
High-dose atomoxetine treatment of ADHD in youths with limited response to standard doses
Christopher J Kratochvil, David Michelson, Jeffrey H Newcorn, et al.
Journal of Child and Adolescent Psychopharmacology
|
November 6, 2007
Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment
Thomas J Spencer, Christopher J Kratochvil, R Bart Sangal, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 18) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 18 results.
Urology
|
March 25, 2017
Prospective Case-crossover Study Investigating the Possible Association Between Nonarteritic Anterior Ischemic Optic Neuropathy and Phosphodiesterase Type 5 Inhibitor Exposure
Evelyn M Flahavan, Hu Li, Komal Gupte-Singh, et al.
Headache
|
November 29, 2020
Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine
Janet H Ford, Tobias Kurth, Amaal J Starling, et al.
Cephalalgia : an International Journal of Headache
|
November 4, 2020
Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine
David W Dodick, Erin G Doty, Sheena K Aurora, et al.
The Journal of Headache and Pain
|
February 26, 2020
Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study
Richard B Lipton, Louise Lombard, Dustin D Ruff, et al.
Cephalalgia : an International Journal of Headache
|
May 21, 2019
Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure
Dustin D Ruff, Janet H Ford, Antje Tockhorn-Heidenreich, et al.
Expert Review of Neurotherapeutics
|
October 22, 2015
Atomoxetine monotherapy compared with combination therapy for the treatment of ADHD: a retrospective chart review study
David B Clemow, Oren W Mason, Elias H Sarkis, et al.
Journal of the American Academy of Child and Adolescent Psychiatry
|
August 23, 2007
High-dose atomoxetine treatment of ADHD in youths with limited response to standard doses
Christopher J Kratochvil, David Michelson, Jeffrey H Newcorn, et al.
Journal of Child and Adolescent Psychopharmacology
|
November 6, 2007
Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment
Thomas J Spencer, Christopher J Kratochvil, R Bart Sangal, et al.
Page
of 2